Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rickenbacher

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
European Journal of Internal Medicine|June 18, 2018
Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?Eva Steinmann, Hans-Peter Brunner-La Rocca, Micha T Maeder, et al.
European Journal of Heart Failure|July 10, 2012
Why and how do elderly patients with heart failure die? Insights from the TIME-CHF studyPeter Rickenbacher, Matthias Pfisterer, Thilo Burkard, et al.
European Journal of Heart Failure|June 29, 2010
Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcomeStephanie Kiencke, Rolf Handschin, Ruth von Dahlen, et al.
European Journal of Heart Failure|March 16, 2017
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)Peter Rickenbacher, Beat A Kaufmann, Micha T Maeder, et al.
European Heart Journal|November 27, 2008
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKETMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter Rickenbacher, et al.
European Journal of Heart Failure|March 27, 2015
Impact of worsening renal function related to medication in heart failureHans-Peter Brunner-La Rocca, Christian Knackstedt, Luc Eurlings, et al.
Journal of the American College of Cardiology|December 19, 2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stentsMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
European Journal of Heart Failure|May 10, 2013
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)Micha T Maeder, Peter Rickenbacher, Hans Rickli, et al.
European Heart Journal|December 14, 2004
Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME)Jacques Claude, Christian Schindler, Gabriela M Kuster, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 4, 2014
Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trialSune Haahr Pedersen, Matthias Pfisterer, Christoph Kaiser, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
European Journal of Internal Medicine|June 18, 2018
Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?Eva Steinmann, Hans-Peter Brunner-La Rocca, Micha T Maeder, et al.
European Journal of Heart Failure|July 10, 2012
Why and how do elderly patients with heart failure die? Insights from the TIME-CHF studyPeter Rickenbacher, Matthias Pfisterer, Thilo Burkard, et al.
European Journal of Heart Failure|June 29, 2010
Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcomeStephanie Kiencke, Rolf Handschin, Ruth von Dahlen, et al.
European Journal of Heart Failure|March 16, 2017
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)Peter Rickenbacher, Beat A Kaufmann, Micha T Maeder, et al.
European Heart Journal|November 27, 2008
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKETMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter Rickenbacher, et al.
European Journal of Heart Failure|March 27, 2015
Impact of worsening renal function related to medication in heart failureHans-Peter Brunner-La Rocca, Christian Knackstedt, Luc Eurlings, et al.
Journal of the American College of Cardiology|December 19, 2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stentsMatthias Pfisterer, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
European Journal of Heart Failure|May 10, 2013
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)Micha T Maeder, Peter Rickenbacher, Hans Rickli, et al.
European Heart Journal|December 14, 2004
Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME)Jacques Claude, Christian Schindler, Gabriela M Kuster, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 4, 2014
Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trialSune Haahr Pedersen, Matthias Pfisterer, Christoph Kaiser, et al.
Pageof 4